Literature DB >> 20091622

Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.

Jenny Mh Chen1, Balraj S Heran, Marco I Perez, James M Wright.   

Abstract

BACKGROUND: Beta-blockers are one of the more commonly prescribed classes of anti-hypertensive drugs, both as first-line and second-line.
OBJECTIVES: To quantify the effect on systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and withdrawals due to adverse effects of beta-blocker therapy when given as a second-line drug in adult patients with primary hypertension. SEARCH STRATEGY: CENTRAL (The Cochrane Library 2009, Issue 2), MEDLINE (1966-Aug 2009), EMBASE (1988-Aug 2009) and bibliographic citations of articles and reviews were searched. SELECTION CRITERIA: Double-blind, randomized controlled trials comparing a beta-blocker in combination with a drug from another class of anti-hypertensive drugs compared with that drug alone for a duration of 3 to 12 weeks in patients with primary hypertension were included. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted the data and assessed trial quality of each included study. MAIN
RESULTS: 20 double-blind RCTs evaluated the BP lowering efficacy of beta-blockers as second-line drug in 3744 hypertensive patients (baseline BP of 158/102 mmHg; mean duration of 7 weeks). The BP reduction from adding a beta-blocker as the second drug was estimated by comparing the difference in BP reduction between the combination and monotherapy groups. A reduction in BP was seen with adding a beta-blocker to thiazide diuretics or calcium channel blockers at doses as low as 0.25 times the manufacturer's recommended starting dose. The BP lowering efficacy of beta-blockers as a second drug was 6/4 mmHg at 1 times the starting dose and 8/6 mmHg at 2 times the starting dose. Beta-blockers reduced heart rate by 10 beats/min at 1 to 2 times the starting dose. Beta-blockers did not statistically significantly increase withdrawals due to adverse effects but this was likely due to the lack of reporting of this outcome in 35% of the included RCTs. AUTHORS'
CONCLUSIONS: Addition of a beta-blocker to diuretics or calcium-channel blockers reduces BP by 6/4mmHg at 1 times the starting dose and by 8/6 mmHg at 2 times the starting dose. When the blood pressure lowering effect of beta-blockers from this review was compared to that of thiazide diuretics from our previous review (Chen 2009), second-line beta-blockers reduce systolic BP to the same extent as second-line thiazide diuretics, but reduce diastolic BP to a greater degree. The different effect on diastolic BP means that beta-blockers have little or no effect on pulse pressure whereas thiazides cause a significant dose-related decrease in pulse pressure. This difference in the pattern of BP lowering with beta-blockers as compared to thiazides might be the explanation for the fact that beta-blockers appear to be less effective at reducing adverse cardiovascular outcomes than thiazide diuretics, particularly in older individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091622     DOI: 10.1002/14651858.CD007185.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  8 in total

1.  Long-chain omega-3 fatty acids and blood pressure.

Authors:  James C Liu; Sarah M Conklin; Stephen B Manuck; Jeffrey K Yao; Matthew F Muldoon
Journal:  Am J Hypertens       Date:  2011-07-14       Impact factor: 2.689

2.  Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D.

Authors:  Paulette D Chandler; Jamil B Scott; Bettina F Drake; Kimmie Ng; John P Forman; Andrew T Chan; Gary G Bennett; Bruce W Hollis; Edward L Giovannucci; Karen M Emmons; Charles S Fuchs
Journal:  Am J Med       Date:  2014-03-20       Impact factor: 4.965

Review 3.  Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.

Authors:  Gavin W K Wong; Heidi N Boyda; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2016-03-10

4.  Time course for blood pressure lowering of beta-blockers with partial agonist activity.

Authors:  Xiao-Yin Zhang; Sam Soufi; Colin Dormuth; Vijaya M Musini
Journal:  Cochrane Database Syst Rev       Date:  2020-09-05

Review 5.  Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing.

Authors:  Anna Vögele; Tim Johansson; Anna Renom-Guiteras; David Reeves; Anja Rieckert; Lisa Schlender; Anne-Lisa Teichmann; Andreas Sönnichsen; Yolanda V Martinez
Journal:  BMC Geriatr       Date:  2017-10-16       Impact factor: 3.921

Review 6.  Beta blockers for peripheral arterial disease.

Authors:  Sharath Chandra Vikram Paravastu; Derick A Mendonca; Anthony Da Silva
Journal:  Cochrane Database Syst Rev       Date:  2013-09-11

7.  Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-12

8.  Preliminary validation of the Hypertension Self-Care Activity Level Effects (H-SCALE) and clinical blood pressure among patients with hypertension.

Authors:  Jan Warren-Findlow; Debra W Basalik; Michael Dulin; Hazel Tapp; Lindsay Kuhn
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-06-25       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.